Search details
1.
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet
; 403(10441): 2293-2306, 2024 May 25.
Article
in English
| MEDLINE | ID: mdl-38705160
2.
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 387(24): 2220-2231, 2022 12 15.
Article
in English
| MEDLINE | ID: mdl-36507690
3.
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
N Engl J Med
; 386(15): 1421-1431, 2022 04 14.
Article
in English
| MEDLINE | ID: mdl-35417637
4.
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 386(4): 351-363, 2022 01 27.
Article
in English
| MEDLINE | ID: mdl-34904799
5.
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Blood
; 142(16): 1348-1358, 2023 10 19.
Article
in English
| MEDLINE | ID: mdl-37369099
6.
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 2024 Mar 27.
Article
in English
| MEDLINE | ID: mdl-38538060
7.
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
Br J Haematol
; 202(1): 40-47, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36971061
8.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Blood
; 137(5): 600-609, 2021 02 04.
Article
in English
| MEDLINE | ID: mdl-33538797
9.
Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic.
Ann Hematol
; 102(1): 107-115, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36369497
10.
COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group.
Ann Hematol
; 102(4): 811-817, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36847805
11.
Technical Note Cell Dysplasia - Cell Dysplastic Features (A Morphological Note).
Folia Biol (Praha)
; 69(1): 34-39, 2023.
Article
in English
| MEDLINE | ID: mdl-37962029
12.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35810754
13.
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas.
Lab Invest
; 102(9): 957-965, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35488033
14.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Article
in English
| MEDLINE | ID: mdl-32731259
15.
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.
Haematologica
; 107(7): 1633-1642, 2022 07 01.
Article
in English
| MEDLINE | ID: mdl-34407602
16.
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Eur J Haematol
; 109(2): 162-165, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35502609
17.
Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
Neoplasma
; 69(6): 1466-1473, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36591807
18.
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
Blood
; 133(9): 919-926, 2019 02 28.
Article
in English
| MEDLINE | ID: mdl-30617197
19.
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT.
Eur J Haematol
; 106(5): 708-715, 2021 May.
Article
in English
| MEDLINE | ID: mdl-33580608
20.
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
N Engl J Med
; 377(14): 1331-1344, 2017 10 05.
Article
in English
| MEDLINE | ID: mdl-28976863